Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norman Putzki

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Journal of the Neurological Sciences|March 29, 2005
High-dose, frequently administered interferon betaVolker Limmroth, Norman Putzki
Therapeutic Advances in Neurological Disorders|December 25, 2010
Natalizumab in the treatment of multiple sclerosisOzgür Yaldizli, Norman Putzki
Current Pain and Headache Reports|June 2, 2010
Headache in multiple sclerosisNorman Putzki, Zaza Katsarava
Swiss Medical Weekly|May 5, 2011
Vitamin D levels in Swiss multiple sclerosis patientsMurat Yildiz, Barbara Tettenborn, Norman Putzki
European Neurology|April 2, 2011
Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetateMurat Yildiz, Barbara Tettenborn, Norman Putzki
JAMA Neurology|September 27, 2016
Rebound Syndrome in Multiple Sclerosis After Fingolimod CessationMartin Merschhemke, Davorka Tomic, Norman Putzki
European Neurology|September 8, 2010
Natalizumab and beyondMurat Yildiz, Barbara Tettenborn, Norman Putzki
Therapeutic Advances in Neurological Disorders|October 20, 2011
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combinationVolker Limmroth, Norman Putzki, Norman J Kachuck
Journal of the Neurological Sciences|June 30, 2009
Multiple sclerosis associated fatigue during natalizumab treatmentNorman Putzki, Ozgür Yaldizli, Barbara Tettenborn, et al.
Expert Review of Clinical Pharmacology|November 14, 2012
Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosisOscar Fernandez, Thomas Berger, Hans-Peter Hartung, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Journal of the Neurological Sciences|March 29, 2005
High-dose, frequently administered interferon betaVolker Limmroth, Norman Putzki
Therapeutic Advances in Neurological Disorders|December 25, 2010
Natalizumab in the treatment of multiple sclerosisOzgür Yaldizli, Norman Putzki
Current Pain and Headache Reports|June 2, 2010
Headache in multiple sclerosisNorman Putzki, Zaza Katsarava
Swiss Medical Weekly|May 5, 2011
Vitamin D levels in Swiss multiple sclerosis patientsMurat Yildiz, Barbara Tettenborn, Norman Putzki
European Neurology|April 2, 2011
Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetateMurat Yildiz, Barbara Tettenborn, Norman Putzki
JAMA Neurology|September 27, 2016
Rebound Syndrome in Multiple Sclerosis After Fingolimod CessationMartin Merschhemke, Davorka Tomic, Norman Putzki
European Neurology|September 8, 2010
Natalizumab and beyondMurat Yildiz, Barbara Tettenborn, Norman Putzki
Therapeutic Advances in Neurological Disorders|October 20, 2011
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combinationVolker Limmroth, Norman Putzki, Norman J Kachuck
Journal of the Neurological Sciences|June 30, 2009
Multiple sclerosis associated fatigue during natalizumab treatmentNorman Putzki, Ozgür Yaldizli, Barbara Tettenborn, et al.
Expert Review of Clinical Pharmacology|November 14, 2012
Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosisOscar Fernandez, Thomas Berger, Hans-Peter Hartung, et al.
Pageof 4